Evaluation of the developmental toxicity of lenalidomide in rabbits
Birth Defects Research Part B Developmental and Reproductive Toxicology2007Vol. 80(3), pp. 188–207
Citations Over Time
Mildred S. Christian, Oscar L. Laskin, Valerie A. Sharper, Alan M. Hoberman, David Stirling, Louise Latriano
Abstract
The maternal and developmental NOAELs for lenalidomide are 3 mg/kg/day. Unlike thalidomide, lenalidomide affected embryo-fetal development only at maternally toxic dosages, confirming that structure-activity relationships may not predict maternal or developmental effects. No fetal malformations were attributable to lenalidomide.
Related Papers
- → Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide(2005)66 cited
- → Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma(2011)24 cited
- → Role of Lenalidomide in the Treatment of Multiple Myeloma and Myelodysplasic Syndrome(2006)20 cited
- [Lenalidomid (Revlimid) in the treatment of multiple myeloma--first experience in the Czech Republic].(2008)
- → Lenalidomide-Induced Diffuse Alveolar Hemorrhage in Patient With Multiple Myeloma(2023)